

12/6/2018; Page 1

Suggested Formula	Calcium Acetate 500 mg Oral Capsules (Powder Blend, 100 x Size #00 Capsules)	FIN	F 003 259
----------------------	--	-----	-----------

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Calcium Acetate, USP	TBD					
Cellulose (Microcrystalline), NF	TBD					
Sodium Chloride, USP	As required					

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information

Hygroscopic (protect from moisture whenever possible):

Calcium Acetate, Cellulose

Sugg

gested Preparatory Guidelines	
Non-Sterile Preparat	ion Sterile Preparation
<u>Processing Error /</u> Testing Considerations:	To account for processing error considerations during preparation, it is suggested to measure an additional 5 to 9% of the required quantities of ingredients.
Special Instruction:	This formula may contain one or more Active Pharmaceutical Ingredients (APIs) that may be classified as hazardous, please refer & verify the current NIOSH list of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016. General Chapter <800> Hazardous Drugs – Handling in Healthcare Settings was formally published February 1, 2016 in the First Supplement to USP 39-NF 34 and has a delayed official implementation date of December 31 st , 2019.
	This formula must be prepared within the appropriate facilities under adequate environmental conditions, following the necessary guidelines and procedures as stated within <i>USP 795</i> and <i>USP 800</i> , when handling hazardous drugs. Only trained and qualified personnel must prepare this formula.
	All required personal protective equipment (hazardous if applicable), such as but not limited to, lab coat, protective sleeves, gloves both inner and outer if applicable, dedicated shoe covers, hairnet, beard cover, eyewear, appropriate face mask, respirator and face shield, etc., where applicable must be worn at all times.
	If applicable, follow all required procedures for hazardous drug handling including but not limited to procurement, transport, storage, preparation, dispensing, administration, clean up (spills) & disposal.
	If you are a registered 503B facility, please refer to all relevant guidance documents including but not limited to the Code of Federal Regulations (CFR), Guidance for Industry (GFIs) and Compliance Policy Guides (CPGs).
	This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



12/6/2018; Page 2

Suggested Formula	Calcium Acetate 500 mg Oral Capsules (Powder Blend, 100 x Size #00 Capsules)	FIN	F 003 259	
----------------------	--	-----	-----------	--

SUGGESTED PREPARATION (for 100 Size #00 Capsules)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor ^(*) :	Processing Error	Qty. to measure
Calcium Acetate, USP §	TBD				
Cellulose (Microcrystalline), NF §	TBD				
Sodium Chloride, USP	As required				

* Takes into account increased batch size conversions and density conversions, if required.

§ Weigh / measure just prior to use.

A. Determine the potency of Calcium Acetate based on the certificate of an	nalysis:
	100%
MINUS	
Water content (from certificate of analysis)	%
DIVIDED BY	100
EQUALS	
Quantity of water free Calcium Acetate, in decimal	
MULTIPLIED BY	
Assay on anhydrous result (from certificate of analysis)	%
DIVIDED BY	100
EQUALS	

/	1	MEDISCA® NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net		12/6/2018; Page 3
	gested		FIN	F 003 259
2.	Ing	redient quantification including processing error adjustments:		
	A.	Determine the quantity (in g) of Calcium Acetate required to make 100 Capsules of Calci	um Ac	etate 500 mg:
		Quantity of Calcium Acetate needed for each capsule		0.500 g
		DIVIDED BY		
		Potency of Calcium Acetate, in decimal (Step 2Ai)	_	
		EQUALS		
		i. Actual Calcium Acetate needed for each capsule	_	g
		MULTIPLIED BY		
		Number of capsules		100
		MULTIPLIED BY		
		Processing error adjustments (5 to 9%):	1	.05 to 1.09
		EQUALS		
		ii. Total Quantity of Calcium Acetate needed <i>plus</i> processing error adjustments:	_	g
3.	Fve	ipient requirements for 100 x Size #00 Capsules		
5.	A.	Calculate the amount of Cellulose (Microcrystalline) required for the batch. Refer to atta details.	ched aj	ppendix for
4.	Pow	der preparation:		
		By geometric addition, combine and triturate the following ingredients together to form a powder blend:	fine, h	omogeneous
		-Calcium Acetate (amount determined in Step 2Aii) -Cellulose (Microcrystalline) (Quantity determined in appendix (I))		
	B.	Pass the above powder mixture through a 40 or 50 mesh sieve.		
	C.	Mix the sieved powder blend using a manual tumbler mixer to ensure homogeneity.		



12/6/2018; Page 4

	Calcium Acetate 500 mg Oral Capsules (Powder Blend, 100 x Size #00 Capsules)	FIN	F 003 259			
5.	5. <u>Product transfer:</u>					
	Fill each of 100 Size #00 capsules with the homogeneous powder blend (Step 4C). Close eac	h capsı	ıle tightly.			
	Clean each capsule by placing the capsules in a container filled with Sodium Chloride, and then gently rolling the container. Pour the container contents into a 10-mesh sieve, and allow the Sodium Chloride to pass through. Finally, roll the capsules on a cloth-covered surface.					
6.	Validation technique:					
	The final weight of each capsule (not including capsule shell) should fall between 90 and 110% of the theoretically calculated weight, in accordance to USP 795 guidelines. The theoretically calculated weight can be determined by adding the amount in appendix (G) + Step 2Ai together.					
7.	Product transfer:					
	Transfer the final product into the specified dispensing container (see "Packaging Requireme	nts").				
JGGE	STED PRESENTATION					

SUGGESTED PRESENTATION

	OCECTED TREDENTATION					
Estimated Beyond-Use Date		6 months, as per USP.*	Packaging Requirements		Tightly closed prescription vial.	
	1	Use as directed. Do not exceed dose.	d prescribed	4	Keep in a dry place	
Auxiliary Labels	2	Keep out of reach of children.		5	Consult your health care practitioner if any other prescription or over-the-counter medications are currently being used or are prescribed for future use.	
3 Keep at room temperature ($20^{\circ}C - 23^{\circ}C$). 6 Cap tightly af		Cap tightly after use.				
Pharmacist Instructions	Ad	d any auxiliary labels specific to t	he active ingr	edie	nt to the dispensing container as deemed necessary.	
Patient Instructions	Co	ntact your pharmacist in the event	of adverse re	actio	ons.	

* The BUD is not later than the time remaining until the earliest expiration date of any API or 6 months, whichever is earlier.



12/6/2018; Page 5

	Suggested Formula	Calcium Acetate 500 mg Oral Capsules (Powder Blend, 100 x Size #00 Capsules)	FIN	F 003 259	
: F		S			
1	Com	ale Les Allers I.V. Les The Art Colores and Technology of Discourse of the Common disc			

R	EF	ER	EN	CE	S
1.1					<u> </u>

1.	Capsule. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding</i> . American Pharmaceutical Association; 1998: 91.
2.	PhosLo. In: Canadian Pharmacists Association. Compendium of Pharmacists and Specialties, 2008. 1704.
3.	Cellulose, Microcrystalline. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients, 4th Edition</i> . American Pharmaceutical Association; 2003: 108.
4.	Sodium Chloride. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients</i> , 4 th Edition. American Pharmaceutical Association; 2003: 556.
5.	Calcium Acetate. In: Sweetman SC, ed. Martindale: The Complete Drug Reference, 34 th Edition. London, England: The Pharmaceutical Press; 2005: 1225.
6.	Calcium Acetate (Monograph). In: O'Neil MJ. <i>The Merck Index 14th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2006: #1646.
7.	Calcium Acetate (Monograph). United States Pharmacopeia XXVIII / National Formulary 23. Rockville, MD. US Pharmacopeial Convention, Inc. 2004: 317.
8.	Calcium Acetate Systemic. Thomson Micromedex. USP DI – Drug Information for the Health Care Professional, 26 th Edition. Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 721.
9.	USP <795>. United States Pharmacopeia XXVIII / National Formulary 23. Rockville, MD. US Pharmacopeial Convention, Inc. 2004: 2457.

DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY, SCHEDULING OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW. MEDISCA NETWORK INC. MAKES NO WARRANTIES WITH RESPECT TO INFRINGEMENT OR NON-INFRINGEMENT BY THE FORMULA OF ANY PATENT OR OTHER INTELLECTUAL PROPERTY OF ANY OTHER PARTY, AND IT IS THE RESPONSIBILITY OF THE PHARMACIST TO INVESTIGATE AND DETERMINE ANY SUCH ISSUE.



12/6/2018; Page 1

Ap	pendix	endix Calculating quantity of excipient required for batch				
Procedure						
1.	Capsule filling:					
	a. For <u>each</u> ingredient powder below, determine the average capsule fill weight by filling and weighing five TARED CAPSULES. Do not forget to divide the total weight by 5 to obtain an <u>average</u> capsule fill weight. Also, crush and triturate the ingredient first if required in formulation.					
	Plug each amount into Step 2, column B.					
2.	Volume Percent Occupied:					
		Ingredients	Column A Quantity Required per capsule	Column B Average capsule fill weight		Column C /B x 100 equals ercent filled
	a. C	a. Calcium Acetate g g%				
	b. C	Cellulose (Microcrystalline)	NYX.	g		
	с. Т	otal (add column C together)	676		-	% (D)
3.	Calculate the quantity of Cellulose (Microcrystalline) required for the batch:					
	a. Percent of Cellulose (Microcrystalline) required = 100% – (D)% (% (E)
	b. Average capsule fill weight of Cellulose (Microcrystalline) (from column B, Step 2b):					g (F)
	c. Quantity of Cellulose (Microcrystalline) required per capsule = $[(E) \div 100 \times (F)]$					g (G)
	d. Total Quantity of Cellulose (Microcrystalline) required for the batch = $100 \text{ capsules} \times (G)$					g (H)
	e. Total quantity of Cellulose (Microcrystalline) <i>plus</i> processing error = $(H) \times 1.05-1.09$ g					g (I)

DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY, SCHEDULING OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW. MEDISCA NETWORK INC. MAKES NO WARRANTIES WITH RESPECT TO INFRINGEMENT OR NON-INFRINGEMENT BY THE FORMULA OF ANY PATENT OR OTHER INTELLECTUAL PROPERTY OF ANY OTHER PARTY, AND IT IS THE RESPONSIBILITY OF THE PHARMACIST TO INVESTIGATE AND DETERMINE ANY SUCH ISSUE.